Avalo Therapeutics, Inc. current report, 20 January 2017

SEC Filing Summary: Cerecor Inc. (8-K)

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Cerecor Inc. on January 20, 2017, regarding events occurring on January 13, 2017. The filing addresses a notice received from the Nasdaq Listing Qualifications Staff concerning the company's failure to meet specific continued listing standards.

Key Financial Metrics and Compliance Status

The filing does not provide specific revenue, profit, cash flow, or debt figures. However, it details the following financial deficiencies identified by Nasdaq:

  • Market Value of Listed Securities (MVLS): Below the minimum requirement of $35 million for the previous 30 consecutive business days.
  • Stockholders' Equity: Failed to maintain the minimum required equity of $2.5 million.
  • Net Income: Failed to report net income from continuing operations in the latest fiscal year or in two of the last three fiscal years.

Material Changes and Regulatory Action

The primary material event is the notification of non-compliance with Nasdaq Listing Rules 5550(b)(1), 5550(b)(2), and 5550(b)(3). This notification has no immediate effect on the listing or trading of the company's common stock or warrants. The company has been granted a 180-calendar-day compliance period, expiring on July 12, 2017, to regain compliance.

Outlook, Risks, and Management Commentary

Management is currently evaluating various courses of action to regain compliance. To satisfy the rules during the compliance period, the company must either:

  1. Achieve an MVLS closing at $35 million or more for a minimum of 10 consecutive business days; or
  2. Report stockholders' equity of at least $2.5 million.

Risks: There is no assurance that the company will be able to regain compliance. Failure to do so by the deadline will result in written notification that the securities are subject to delisting, at which point the company may appeal the determination.

Key Facts for Investor Verification

  • Verify the current market capitalization and stock price trends to assess the feasibility of meeting the $35 million MVLS threshold.
  • Review the most recent audited financial statements to confirm the stockholders' equity balance and net income status.
  • Monitor for any subsequent filings regarding capital raises or strategic actions taken to address the delisting notice.
  • Confirm the exact expiration date of the compliance period (July 12, 2017) and any potential extensions.